Cargando…

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

BACKGROUND: Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of GLP-1ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chun-Ting, Yang, Chen-Yi, Ou, Huang-Tz, Kuo, Shihchen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293792/ https://www.ncbi.nlm.nih.gov/pubmed/32534570 http://dx.doi.org/10.1186/s12933-020-01053-0

Ejemplares similares

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study
por: Peng, Zi-Yang, et al.
Publicado: (2023)

Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes
por: Yang, Chen-Yi, et al.
Publicado: (2020)

Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases
por: Kuo, Shihchen, et al.
Publicado: (2021)

Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan
por: Peng, Zi-Yang, et al.
Publicado: (2022)

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
por: Caruso, Irene, et al.
Publicado: (2022)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective
por: Su, Hsuan-Yu, et al.
Publicado: (2023)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
por: Zhang, Zeqing, et al.
Publicado: (2017)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future
por: Kuo, Shihchen, et al.
Publicado: (2021)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
por: Yang, Chun-Ting, et al.
Publicado: (2022)

Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies
por: Yang, Chen-Yi, et al.
Publicado: (2022)

Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysis
por: Su, Pei-Fang, et al.
Publicado: (2020)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
por: Zhou, Yu, et al.
Publicado: (2022)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
por: Hausenloy, Derek J, et al.
Publicado: (2013)

Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice
por: Díaz-Megido, Claudia, et al.
Publicado: (2023)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
por: Yamada, Takayuki, et al.
Publicado: (2021)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ee24d5teja1k5kq7b35tmjao5g